AOD-9604: Research Overview
AOD-9604 is a stabilized synthetic analog of the C-terminal fragment (amino acids 176–191) of human growth hormone. It is studied for lipolytic activity in adipose tissue research without the IGF-1 stimulation associated with full-length growth hormone.
How it differs from full-length HGH
AOD-9604 corresponds only to the C-terminal fragment of human growth hormone, modified with a tyrosine at the N-terminus. Unlike intact hGH, research indicates AOD-9604 does not bind the growth hormone receptor or stimulate IGF-1 production, meaning it does not produce the anabolic, hyperglycemic, or epiphyseal effects of exogenous GH. This separation of lipolytic activity from GH-receptor signaling is the central reason it is studied.
Lipolysis research
Animal studies published in the early 2000s reported dose-dependent lipolytic (fat-mobilizing) activity and inhibition of lipogenesis in adipocytes, with research focusing on interaction with beta-adrenergic receptors in adipose tissue. The compound received GRAS (Generally Recognized As Safe) status from the FDA for certain food applications, reflecting a favorable tolerability profile in those evaluations.
Purity and verification
Pokai Research AOD-9604 is supplied as a research-grade peptide at 99.5% purity. Batch-specific Certificate of Analysis documentation is available on request via the product page.
Frequently asked questions
How does AOD-9604 differ from full-length growth hormone in its metabolic effects?
AOD-9604 is a synthetic analog of the C-terminal fragment (residues 177–191) of human growth hormone, modified with a tyrosine at the N-terminus. Unlike full-length hGH, AOD-9604 does not bind the growth hormone receptor or stimulate IGF-1 production, meaning it does not produce the anabolic, hyperglycemic, or epiphyseal effects of exogenous GH. Research has focused on its interaction with beta-adrenergic receptors in adipose tissue as a potential mechanism for selective lipolysis. Animal studies have demonstrated fat-mobilizing activity without the metabolic side effects associated with intact GH.
Source: Mol Cell Endocrinol (2001) · PubMedHow is peptide purity measured and why does it matter?
Peptide purity is typically assessed by reverse-phase high-performance liquid chromatography (HPLC) and confirmed by mass spectrometry. These techniques quantify the proportion of the target compound relative to impurities such as deletion sequences, oxidized variants, or solvent residues. Research applications require high purity — commonly ≥98% — to ensure that observed biological effects can be attributed to the intended molecule rather than contaminants. Independent third-party certificates of analysis (COAs) provide an objective record of purity at the time of synthesis.
Source: J Pept Sci (2019) · PubMedWhat is a Certificate of Analysis (COA)?
A Certificate of Analysis (COA) is a document from an accredited analytical laboratory confirming a compound's identity, purity, and potency. For research peptides it typically includes HPLC chromatograms and mass spectrometry data. Independent third-party COAs are the gold standard for verifying compound quality.
Source: USP General Chapter ⟨1058⟩ · PubMed